1. Roche Diagnostics Launches Its First China-Manufactured Real-Time Fluorescent Quantitative PCR Instrument LC PRO

On December 3, 2025, at the first "Sino-Swiss Innovation Day" co-hosted by the Swiss Chamber of Commerce and Roche Diagnostics Suzhou, Roche Diagnostics announced the official launch of its first domestically produced real-time fluorescent quantitative PCR instrument LC PRO in China. This instrument was designed, developed and manufactured by Roche Diagnostics' local team, aiming to continuously empower local scientific research innovation, meet the unmet needs of molecular laboratories, and benefit more Chinese patients. As Roche's largest single investment project in China, the new investment project at the Suzhou base broke ground in 2025.

2. Tongshu Gene Signs MRD Technology Licensing Agreement with Nasdaq-Listed Company, with Southeast Asia as the First Launch Market

On December 6, 2025, Wuxi Tongshu Biotechnology Co., Ltd. (Tongshu Gene) officially announced that it has reached a globally strategic licensing agreement with BioNexus Gene Lab Corp., a Nasdaq-listed company, to license its independently developed core technology - the "Zhenxin'an-MRD" minimal residual disease monitoring platform to BGLC and its partners, with the Southeast Asian market as the first stop, to jointly promote the global commercialization of this technology. In the first phase, it will first complete the market access, localized promotion and commercial application of the VitaGuard™ platform (based on "Zhenxin'an-MRD" technology) in the Association of Southeast Asian Nations (ASEAN) region, including core countries such as Singapore, Malaysia, and Thailand.

3. BSBE Enters Strategic Cooperation with Diasorin to Usher in a New Chapter of Precision Diagnostics

On December 3, 2025, Beijing Strong Biotechnologies, Inc. officially signed a strategic cooperation agreement with Diasorin, a world-renowned diagnostic company. Diasorin is a leader in the global field of immunoassay and molecular diagnostics, focusing on specialty and routine immunoassays. This cooperation will deeply synergize the advantageous resources of both parties, jointly open a new chapter in the innovative development of precision diagnostics, and promote the localized R&D and production of diagnostic products.

4. Azerbaijani Delegation Visits Orienter to Explore New Cooperation Opportunities

On December 2nd, 2025, a delegation from Azerbaijan paid a visit to Sichuan Orienter Bioengineering Co., Ltd's Technology Innovation Park. The delegation spoke highly of Orienter's systematic technical capabilities and professionalism demonstrated in the B2B and B2C markets. The comprehensive strength of Orienter has laid a solid foundation for both parties to deepen strategic cooperation and achieve long-term mutual benefit and win-win results. Taking this exchange as an opportunity, the two sides will further expand cooperation areas, promote the implementation of pragmatic projects, and contribute to the high-quality development of the medical and health undertakings of both countries.